Journal article
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy
DA Carney, DA Westerman, CS Tam, A Milner, HM Prince, M Kenealy, M Wolf, EH Januszewicz, D Ritchie, N Came, JF Seymour
Leukemia | Published : 2010
DOI: 10.1038/leu.2010.218
Abstract
Fludarabine combination chemotherapy achieves high response rates in chronic lymphocytic leukemia (CLL) and indolent lymphoma. The aim of this study was to investigate the incidence and characteristics of treatment-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) after treatment with fludarabine in combination for lymphoproliferative disorders and identify risk factors for its development. In all, 176 patients treated with fludarabine combination were followed for a median of 41 months (range 6-125 months). In all, 19 cases of t-MDS/AML have been identified for an overall rate of 10.8%. Median overall survival post-t-MDS/AML diagnosis was 11 months. Patients developing t-MDS/AML..
View full abstract